Inclisiran Cuts LDL by 47% Without Statins in Primary Prevention Patients
A phase 3 trial shows inclisiran monotherapy slashes LDL cholesterol nearly 47% in low-risk adults not on any lipid-lowering therapy.
Summary
The VICTORION-Mono trial tested inclisiran — a twice-yearly injectable siRNA drug — as a standalone therapy in 350 adults without cardiovascular disease or diabetes. Participants had moderately elevated LDL (average 135 mg/dL) and low 10-year heart disease risk. After 6 months, inclisiran reduced LDL by 46.5% versus a 1.4% change with placebo and just 11.2% with ezetimibe. The drug also lowered PCSK9 and lipoprotein(a) levels. The trial included a notably diverse population — over 60% women and nearly 40% Hispanic/Latino participants. Inclisiran was well tolerated with no new safety signals, marking the first evidence of its effectiveness as monotherapy in a primary prevention setting.
Detailed Summary
Elevated LDL cholesterol remains one of the most modifiable risk factors for cardiovascular disease, yet many people with borderline-high LDL and no diagnosed heart disease go untreated. Current guidelines often reserve aggressive lipid-lowering for higher-risk patients, leaving a gap in primary prevention — especially for those who cannot tolerate statins.
The VICTORION-Mono trial addressed this gap by testing inclisiran, an RNA interference (siRNA) therapy that silences PCSK9 production in the liver, as a monotherapy in adults without ASCVD, diabetes, or familial hypercholesterolemia. The 6-month, phase 3, randomized, double-blind trial enrolled 350 participants aged 18–75 with fasting LDL between 100–190 mg/dL and a low 10-year cardiovascular risk score (median 2.2%). Participants received inclisiran, ezetimibe, or placebo in a 2:1:1 ratio.
The results were striking. Inclisiran achieved a mean LDL reduction of 46.5% from baseline at day 150, compared to 11.2% for ezetimibe and 1.4% for placebo — a statistically significant superiority over both comparators (P < 0.0001). PCSK9 levels and lipoprotein(a), an independent cardiovascular risk marker, were also meaningfully reduced. The drug was well tolerated with no new safety concerns identified.
These findings are clinically significant for longevity-focused medicine. Inclisiran's twice-yearly dosing (after initial and 3-month doses) offers a major adherence advantage over daily pills. For primary prevention populations who are statin-intolerant or statin-naive, it may represent a viable alternative to achieve meaningful LDL reduction.
Important caveats apply: the trial ran only 6 months and was funded by Novartis, the drug's manufacturer. Long-term cardiovascular outcome data in this primary prevention population are not yet available, and cost-effectiveness at the population level remains an open question.
Key Findings
- Inclisiran monotherapy reduced LDL-C by 46.5% from baseline at day 150 vs 1.4% for placebo.
- Inclisiran outperformed ezetimibe by 35.4 percentage points in LDL reduction (P < 0.0001).
- PCSK9 and lipoprotein(a) levels also showed favorable reductions with inclisiran.
- Trial enrolled a diverse cohort: 62.6% female, 39.7% Hispanic/Latino, 10.6% Black or African American.
- No new safety signals identified; inclisiran was well tolerated as monotherapy.
Methodology
VICTORION-Mono was a 6-month, phase 3, randomized, double-blind, multicenter trial with three arms: inclisiran, ezetimibe, and placebo (2:1:1 ratio) in 350 adults without ASCVD or lipid-lowering therapy. The primary endpoint was percentage change in LDL-C at day 150. The study was funded by Novartis, and multiple authors are Novartis employees.
Study Limitations
The trial lasted only 6 months and did not assess hard cardiovascular outcomes such as heart attack or stroke. Novartis funding and author conflicts of interest introduce potential bias. The low baseline cardiovascular risk of participants (median 10-year risk 2.2%) limits generalizability to higher-risk populations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.